India, June 24 -- GeneDx Holdings Corp. (WGS) is trading at $90.00, up 12.91 percent, or $10.29 on Tuesday, after the American Academy of Pediatrics updated its guidance to recommend exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability.
The stock opened at $83.19 and has traded between $82.01 and $91.00 so far today on the Nasdaq. Volume stands at 1.21 million shares, slightly above the average of 1.13 million. The 52-week range for the stock is $24.91 to $117.75.
The move highlights the value of early genomic testing in improving diagnoses and outcomes, which GeneDx is well positioned to support.
For comments and feedback contact: editorial@rttnews.com
Published by HT D...